5T4-modified vaccinia ankara: Progress in tumor-associated antigen-based immunotherapy

Expert Opinion on Biological Therapy

Volumn 7, Issue 9, 2007, Pages 1463-1469

  Amato, Robert J ^a  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

5T4; Cancer; Immunotherapy; Tumor associated antigen; Vaccinia ankara

Indexed keywords

ALPHA INTERFERON; ANDROGEN; CANCER VACCINE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; OXALIPLATIN; PROSTATE SPECIFIC ANTIGEN; TROVAX; TUMOR ANTIGEN; TUMOR ANTIGEN 5T4; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VECTOR;

CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL ADHESION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; KIDNEY CARCINOMA; LONGEVITY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR CELL; VACCINIA VIRUS;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; NEOPLASMS; VACCINIA VIRUS;

MURINAE;

EID: 34748820827     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.9.1463     Document Type: Review

References (35)

1. HARROP R, JOHN J, CARROLL MW: Recombinant viral vectors: cancer vaccines. Adv. Drug Delivery Rev. (2006) 58(8):931-947.
2. HARROP R, CARROLL MW: Viral vectors for cancer immunotherapy. Front. Biosci. (2006) 11:804-817.
3. + T cell dependent and antibody mediated. Cancer Immunol. Immunother. (2006) 55(9):1081-1090.
4. HARROP R, CONNOLLY NB, REDCHENKO I et al.: Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II Trial. Clin Cancer Res. (2006) 12(11):3416- 3424.
5. HARROP R, DRURY N, SHINGLER W et al.: Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses (2007) (In Preparation).
6. HARROP R, HAWKINS RE, ANTHONEY A et al.: An open label Phase II study of modified vaccinia ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with chemotherapy: safety and immunogenicity before, during and after chemotherapy. J. Clin Oncol. Proceedings of the 2005 ASCO Annual Meeting (2005) 23(16S):2578.
7. DANGOOR A, BURT D, HARROP R et al.: A vaccinia-based vaccine (TroVax) targeting the oncofetal antigen 5T4 administered before and after surgical resection of colorectal cancer liver metastases: Phase II trial. J. Clin Oncol. Proceedings of the 2006 ASCO Annual Meeting (2006) 24(18S):2574.
8. KAUFMAN HL, DERAFFELE G, MITCHAM J et al.: A Phase I clinical trial of MVA expressing 5T4 and high-dose interleukin-2 (IL-2) for metastatic renal cell carcinoma. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I (2006) 24(18S):12500.
9. CAO A, HERNANDEZ-MCCLAIN J, WILLIS J et al.: Activity of MVA 5T4 alone or in combination with either interleukin-2, interferon-α in patients with metastatic renal cell cancer. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings Part I (2007) 25(18S):135s (Abstract no. 3069).
10. AMATO R, KAREDIY M, CAO A et al.: Phase II trial to assess the activity of MVA 5T4 (TroVax) alone versus MVA 5T4 plus granulocyte macrophage colony-stimulating factor in patients with progressive hormone refractory prostate cancer. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings Part I (2007) 25(18S):241s (Abstract no. 5026).
11. HOLE N, STERN PL: A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br. J. Cancer (1988) 57:237-246.
12. SOUTHALL P, BOXER G, BAGSHAW K et al.: Immunological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer (1990) 61:89-95.
13. STARZYNSKA T, MARSH P, SCHOFIELD P et al.: Prognostic significance of 5T4 oncofoetal antigen expression in colorectal carcinoma. Br. J. Cancer (1994) 69:899-902.
14. GRIFFITHS RW, GILHAM DE, DANGOOR A et al.: Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br. J. Cancer (2005) 93(6):670-677.
15. BARROW KM, WARD CM, RUTTER J, ALI S, STERN PL: Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Devel. Dynamics (2005) 233(4):1535-1545.
16. CARSBERG C, MYERS KA, STERN PL: Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in ephithelial cells. Int. J. Cancer (1996) 68(1):84-92.
17. CARROLL MW, RESTIFO NP: Poxviruses as vectors for cancer immunotherapy. In: Cancer Vaccines and Immunotherapy. Stern PL, Peter CL, Beverly MC. (Eds), Cambridge University Press, Cambridge, UK (2000):47-65.
18. SUTTER G, MOSS B: Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA (1992) 89:10847- 10851.
19. ROCHLITZ C, FIGLIN R, SQUIBAN P et al.: Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. (2003) 5(8):690-699.
20. EDER J, KANTOFF P, ROPER K et al.: A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6(5):1632-1638.
21. MARSHALL J, HOYER R, TOOMEY M et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18(23):3964-3973.
22. MARLOW S: Trovax Gene Therapy Vaccine Product: Investigator's Brochure, Oxford Biomedica, Oxford, UK (2006).
23. REDCHENKO I, HARROP R, RYAN MG, HAWKINS RE, CARROLL MW: Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology (2006) 118:50-57.
24. MOTZER R, MAZUMDAR M, BACIK J et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. (1999) 17:2530-2540.
25. YANG J, SHERRY R, STEINBERG S et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21:3127-3132.
26. TANNOCK I, DE WIT R, BERRY W et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl J. Med. (2004) 351(15):1502-1512.
27. PETRYLAK D, TANGEN C, HUSSAIN M et al.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. (2004) 351(15):1513-1520.
28. RINI B, BOK R, SMALL E: Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J. Clin. Oncol. (2003) 21(1):99-105.
29. SMALL E, REESE D, UM B et al.: Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. (1999) 5:1738-1744.
30. ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):125-134.
31. MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):115-124.
32. HUANG S, HOUGHTON P: Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. (2003) 3(4):371-377.
33. DUTCHER J, HUDES G, MOTZER R: Preliminary report of a Phase I study of intravenous (IV) CCI-779 given in combination with interferon-(IFN) to patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin Oncol. (2003) 22:213 (Abstract 854).
34. HUDES G, CARDUCCI M, TOMCZAK P et al.: Temsirolimus, interferon-α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. (2007) 356(22):2271-2281.
35. SCHLOM J, ARLEN P, GULLEY J: Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res. (2007) 13(13):3776-3781.